CRP reductions with Leronlimab in the setting of severe COVID19 in addition to NASH have also been seen so I think it is a valid and logical marker for a primary endpoint. It is a very well recognized and common lab for clinicians so would be a useful marker during treatment post-approval.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...gure%202I).

Also (see figure 1):
https://pubmed.ncbi.nlm.nih.gov/33521616/